Key result
Percutaneous left atrial appendage occlusion in 8 hemodialysis patients with nonvalvular atrial fibrillation resulted in 0 deaths, cardioembolic events, or major bleeding over 14.24 months.
Why the study?
Evidence regarding the effectiveness and safety of oral anticoagulation in patients on hemodialysis is conflicting and scarce, prompting evaluation of percutaneous LAAO in this population.
Does percutaneous left atrial appendage occlusion provide a safe alternative to anticoagulation for stroke prevention in hemodialysis patients with nonvalvular atrial fibrillation?
Observational (n=8)
No
Does percutaneous left atrial appendage occlusion provide a safe alternative to anticoagulation for stroke prevention in hemodialysis patients with nonvalvular atrial fibrillation?
Percutaneous LAAO appears to be a feasible and safe alternative to oral anticoagulation in hemodialysis patients with NVAF and a history of major bleeding.
Supports LAAO feasibility in hemodialysis patients with AF; hypothesis-generating and requires prospective trials before practice change.
The evidence about the effectiveness and safety of oral anticoagulation in patients on hemodialysis is conflicting and scarce. Percutaneous left atrial appendage occlusion (LAAO) has demonstrated to be a valid alternative therapeutic option for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). The aim of this study is to present the outcomes of percutaneous LAAO in patients with end-stage renal disease (ESRD) on hemodialysis and NVAF in our center. We conducted a retrospective review of clinical records, demographics, LAAO procedure, complications, and outcomes of patients with NVAF and ESRD on hemodialysis who underwent a percutaneous LAAO in our center between January 2017 and January 2019. In the period of the study, eight patients with ESRD on hemodialysis underwent a percutaneous LAAO in our center. The overall mean age was 67.5 years (range 56-81; SD ± 7.2). All patients had permanent NVAF. The total mean dialysis duration was 8.49 years (range 0.83-14.8; SD ± 6.2). The mean CHA2DS2-VASc and HAS-BLED scores were high (4.75 [SD ± 1.16] and 4.62 [SD ± 0.91], respectively). All patients had history of a major hemorrhagic event (BARC Score ≥3). Most patients (n = 6) showed left ventricular hypertrophy, and the average LVEF was 54% (SD ± 6.5). All devices were implanted successfully. Postprocedural antithrombotic regimen prescribed was based on antiplatelet therapy. No deaths, cardioembolic events, or major bleeding (according to the BARC scale) were reported during a mean follow-up of 14.24 months (SD ± 9.44). Percutaneous LAAO could be of particular interest in patients with NVAF and CKD in hemodialysis. Further studies will be necessary to confirm this hypothesis.
No takes yet. Share an insight, caveat, or question.
Xipell et al. (2019) conducted an observational in Nonvalvular atrial fibrillation and end-stage renal disease on hemodialysis (n=8). Percutaneous left atrial appendage occlusion (LAAO) was evaluated on Deaths, cardioembolic events, or major bleeding. Percutaneous left atrial appendage occlusion in 8 hemodialysis patients with nonvalvular atrial fibrillation resulted in 0 deaths, cardioembolic events, or major bleeding over 14.24 months.